Adverse Reactions Analysis and Prediction Model of Cefoperazone Sodium Sulbactam Sodium

Xing LIU; Yuan LIU; Xiang-fang LIU; Jie CHEN; Yong-gang CHEN; Hui SUN; Ling MA

doi:10.12259/j.issn.2095-610X.S20210622

Volume 42 Issue 6

Jul. 2021

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2021 > 42(6): 139-145

Xing LIU, Yuan LIU, Xiang-fang LIU, Jie CHEN, Yong-gang CHEN, Hui SUN, Ling MA. Adverse Reactions Analysis and Prediction Model of Cefoperazone Sodium Sulbactam Sodium[J]. Journal of Kunming Medical University, 2021, 42(6): 139-145. doi: 10.12259/j.issn.2095-610X.S20210622

Citation:

Xing LIU, Yuan LIU, Xiang-fang LIU, Jie CHEN, Yong-gang CHEN, Hui SUN, Ling MA. Adverse Reactions Analysis and Prediction Model of Cefoperazone Sodium Sulbactam Sodium[J]. Journal of Kunming Medical University, 2021, 42(6): 139-145. doi: 10.12259/j.issn.2095-610X.S20210622

Citation:

PDF( 712 KB)

Adverse Reactions Analysis and Prediction Model of Cefoperazone Sodium Sulbactam Sodium

doi: 10.12259/j.issn.2095-610X.S20210622

1.
Pharmacy Department of Kunming Third People’s Hospital，Kunming Yunnan 650041
2.
Pharmacy Department of the First People’s Hospital of Yunnan，Kunming Yunnan 650032，China

Received Date: 2021-03-26
Available Online: 2021-07-03
Publish Date: 2021-07-21

Abstract

Abstract

Objective To analyze the safety of cefoperazone Sodium and Sulbactam Sodiumfor injection in Kunming medical institutions, explore the influencing factors of adverse reactions （ADR） and the correlation between the factors, so as to construct the prediction model of adverse reactions, and provide reference for the rational application ofcefoperazone Sodium and Sulbactam Sodium in clinical practice. Methods From January 2015 to June 2020, 222 adverse reaction reports of cefoperazone sodium and sulbactam sodium for injection in the Kunming City Adverse Drug Reaction Report Monitoring Database were extracted as the observation group. During the same period, no adverse reaction occurred when using cefoperazone sodium and sulbactam sodium for injection, The 250 responding cases were used as the control group. The clinical data of the two groups of patients were collected, and the relationship between the factors was analyzed through correlation; the related factors of adverse reactions were analyzed by multivariate logistic regression, and the prediction of adverse reactions was constructed according to the results Model. Evaluate the effectiveness of predictive models through receiver operating characteristic （ROC） curves. Results Correlation analysis showed that age was positively correlated with the number of primary diseases （Kendall’ s tau-b = 0.764, P < 0.05）. There was a negative correlation between medication time and hospital stay （r = -0.124, P < 0.05）. Multivariate logistic regression analysis showed that retirees, patients with liver and kidney dysfunction, and medication time （11-15） days were related factors for the adverse reactions of cefoperazone sodium and sulbactam sodium. The prediction model is logit （P）= 1.357 + 1.739 × retirees + 3.485 × liver and kidney damage + 2.681 × days of medication （11-15）. The area under the ROC curve of this model is 0.877, and the sensitivity and specificity are 91.8% and 77.4%, respectively. Conclusion Liver and kidney dysfunction patients, medication time （11～15） d are the related factors of adverse reactions of Cefoperazone Sodium and Sulbactam Sodiumand the prediction model has high clinical value.
- Cefoperazone sodium and sulbactam sodium for snjection,
- Adverse drug reactions,
- Prediction model

FullText(HTML)

References(22)

References

[1]	金晶,李青,冷光. 头孢哌酮/他唑巴坦不良反应风险因素分析[J]. 药物流行病学杂志,2016,25(6):346-349.
[2]	刘宪军,付娜. 109例头孢哌酮钠舒巴坦钠不良反应报告分析[J]. 中国药物警戒,2014,11(6):355-357.
[3]	胡新春,邓超英. 呼吸内科抗菌药物的临床应用与分析研究[J]. 国际呼吸杂志,2015,35(21):1617-1619. doi: 10.3760/cma.j.issn.1673-436X.2015.21.004
[4]	陈菲,王璐,王静. 肺炎克雷伯菌耐药与抗菌药物使用强度现况及其关联分析[J]. 蚌埠医学院学报,2019,44(8):1091-1096.
[5]	程英,段菲,权晨. 注射用头孢哌酮钠他唑巴坦钠配伍禁忌临床分析[J]. 中国药业,2019,28(3):73-75. doi: 10.3969/j.issn.1006-4931.2019.03.024
[6]	栗啸阳,郭代红,刘思源,等. 13458例头孢菌素类药品不良反应报告分析[J]. 药物流行病学杂志,2020,29(3):166-169.
[7]	张士洋,程军,陈志武. 350例头孢菌素类抗生素不良反应报告分析[J]. 安徽医药,2011,15(4):516-518. doi: 10.3969/j.issn.1009-6469.2011.04.053
[8]	何云开,刘产明,曾晓辉. 头孢哌酮钠/舒巴坦钠致喉头水肿及过敏性休克各1例[J]. 江苏药学与临床研究,2004,12(S1):76-76.
[9]	王全一,李彦博,傅蓉. 高效凝胶色谱法测定注射用头孢哌酮钠他唑巴坦钠中的高聚物[J]. 中国药业,2013,22(12):83-84. doi: 10.3969/j.issn.1006-4931.2013.12.053
[10]	钟雪,刘田,冯婉玉. 他唑巴坦致过敏反应案例报道及文献复习[J]. 中国新药杂志,2019,28(14):1784-1788. doi: 10.3969/j.issn.1003-3734.2019.14.020
[11]	石姗平,吴雪,农杰昌,等. 头孢哌酮/舒巴坦致凝血功能异常的影响因素分析[J]. 药物流行病学杂志,2019,28(9):578-580.
[12]	庞立峰. 注射用头孢哌酮钠舒巴坦钠致凝血功能异常1例[J]. 中国药物警戒,2018,15(5):62-63.
[13]	田艳平,朱燕,尹红,等. 46例注射用头孢哌酮/舒巴坦致过敏性休克分析[J]. 中国药物警戒,2010,7(4):246-248. doi: 10.3969/j.issn.1672-8629.2010.04.019
[14]	代蓉,邹玲,赵丽,李晓华,等. 1例头孢哌酮钠他唑巴坦钠过敏性休克病人的急救护理[J]. 护理研究,2015,29(23):2939-2939. doi: 10.3969/j.issn.1009-6493.2015.23.057
[15]	宋明辉,张建伟,张荣厚. 注射用头孢哌酮钠他唑巴坦钠静脉滴注致过敏性休克1例[J]. 海峡药学,2020,32(1):210-211. doi: 10.3969/j.issn.1006-3765.2020.01.090
[16]	施毅,李培. 根据药代动力学/药效动力学理论合理使用氨基糖苷类抗生素[J]. 中华结核和呼吸杂志,2012,35(10):726-728. doi: 10.3760/cma.j.issn.1001-0939.2012.10.004
[17]	马亚松,李敏,贾玉捷,孙燕,杨宏硕. 注射用头孢哌酮钠他唑巴坦钠与输液配伍稳定性研究[J]. 化工管理,2020,10(4):95-96. doi: 10.3969/j.issn.1008-4800.2020.04.061
[18]	金晶,李青,冷光. 山西省头孢哌酮钠他唑巴坦钠不良反应报告分析[J]. 山西医药杂志,2016,45(10):1159-1161.
[19]	张扣兴,唐英春,毕筱刚,等. 头孢哌酮钠/他唑巴坦钠体外抗菌活性和影响因素[J]. 中国临床药理学杂志,2001,17(3):195-198. doi: 10.3969/j.issn.1001-6821.2001.03.010
[20]	朱芸. 浅析静脉滴注头孢哌酮/他唑巴坦所致不良反应的特点[J]. 健康必读,2019(23):16-17.
[21]	范晓. 浅析静脉滴注头孢哌酮/他唑巴坦所致不良反应的特点[J]. 当代医药论丛,2017,15(3):8-9. doi: 10.3969/j.issn.2095-7629.2017.03.006
[22]	张楠,郭晓昕,贾海忠. 避免药物不良反应发生的方法学研究进展[J]. 中国药物警戒,2020,17(1):56-62.

Relative Articles(20)

Relative Articles

[1]	Dongyan LIU, Yan LIU, Zhiming REN, Feng WANG, Yong WANG. Analysis of Risk Factors for Chemotherapy Induced Myelosuppression and Construction of Prediction Models for Myelosuppression Based on Logistic Regression Analysis in Cancer Patients. Journal of Kunming Medical University, 2025, 46(): 1-8.
[2]	Yuanzhen WANG, Hongyan WEI, Renhai TIAN, Yongzhen Chen, Danqing XU, Yingyuan ZHANG, Lixian CHANG, Chunyun LIU, Li LIU. Establishment and Evaluation of a Risk Prediction Model for Chronic Liver Failure Complicated by Primary Hepatocellular Carcinoma Before Intervention. Journal of Kunming Medical University, 2025, 46(3): 1-9.
[3]	Jun DENG, Jun WANG, Xi WANG, Change GAO, Xiao CHEN, Mingxia SHI. Prediction Model and Its Value of IrAEs Based on Peripheral Blood Markers. Journal of Kunming Medical University, 2025, 46(): 1-10.
[4]	Wenxiu XU, Xiaofeng MO, Xiangmin YANG, Silu YANG, Fan WU, Te LI. Application of Logistic Regression and Decision Tree Model in Prediction of Adverse Reactions of Iodinated Contrast Medium. Journal of Kunming Medical University, 2024, 45(9): 70-75. doi: 10.12259/j.issn.2095-610X.S20240911
[5]	Yanmei JI, Wenjun LI, Qingyun LI, Ni GUO, Ni MENG, Dan ZHOU, Qiuyu LI, Xingfang JIN. The Analysis of Related Factors of Cognitive Impairment after the Acute Ischemic Stroke and Construction of Nomogram Model. Journal of Kunming Medical University, 2024, 45(5): 73-81. doi: 10.12259/j.issn.2095-610X.S20240511
[6]	Huijuan ZENG, Bo TIAN, Hongling YUAN, Jie HE, Guanxi LI, Guojia RU, Min XU, Dong ZHAN. Predictive Modeling of Chronic Kidney Disease with Hypertension or Diabetes Based on Machine Learning Algorithms. Journal of Kunming Medical University, 2024, 45(3): 99-105. doi: 10.12259/j.issn.2095-610X.S20240315
[7]	Jingyu YANG, Ning XU, Yutao ZHANG, Fengchang HUANG, Yuanming JIANG, Liang YIN. Comparative Study of Multiple Models Based on Baseline T2WI Images for Predicting Pathological Complete Remission of Progressive Rectal Cancer after Neo-adjuvant Chemoradiotherapy. Journal of Kunming Medical University, 2023, 44(5): 117-124. doi: 10.12259/j.issn.2095-610X.S20230512
[8]	Min ZHOU, Zhihui MA, Jiayan LI, Jianhua FAN, Ling LIN, Tingying YU, Huifang ZHANG, Li LIU. Predictive Model of Risk Factors for the Recurrence of Liver Cirrhosis with Pleural Effusion. Journal of Kunming Medical University, 2022, 43(5): 149-154. doi: 10.12259/j.issn.2095-610X.S20220524
[9]	Ji JIA, Siming TAO. Development of A Plasma Osmolality Prediction Model for the Risk of In-hospital Death in Critically Ill Patients with Acute ST-segment Elevation Myocardial Infarction. Journal of Kunming Medical University, 2022, 43(12): 58-65. doi: 10.12259/j.issn.2095-610X.S20221212
[10]	Hong WANG, Dexing YANG, Qiang WANG, Weiyu ZHOU, Jiefu TANG, Zhenfang WANG, Kai FU, Shengzhe LIU, Rong LIU. Risk Factors Analysis and Prediction Model Establishment of Refeeding Syndrome in ICU Patients with Sepsis. Journal of Kunming Medical University, 2022, 43(11): 44-51. doi: 10.12259/j.issn.2095-610X.S20221102
[11]	Guimei ZHANG, Shu CHEN, Yunhua SONG, Yang WU, Hongyuan ZHOU. Risk Factors of Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Establishment of Risk Prediction Model. Journal of Kunming Medical University, 2022, 43(8): 184-190. doi: 10.12259/j.issn.2095-610X.S20220830
[12]	Jing-rong DAI, Jie LI, Xu HE, Yang LI, Yan LI. Risk Factors Analysis and Risk Prediction Model Construction of Depression in Inpatients of Geriatrics Department of a Hospital in Yunnan. Journal of Kunming Medical University, 2021, 42(11): 20-26. doi: 10.12259/j.issn.2095-610X.S20211104
[13]	Wang Li Li . . Journal of Kunming Medical University, 2019, 40(05): 117-121.
[14]	Shi Xiao Qing , Feng Ji Hong . . Journal of Kunming Medical University, 2019, 40(02): 86-91.
[15]	Liu Qing Hua . The Effect of Propofor Combined with Shufen on Analgesia，Analepsia and Adverse Reactions of Laparoscopic Myomectomy. Journal of Kunming Medical University,
[16]	Liu Ping . Effect of Intravenous Injection of Dezocine on the Incidence of Adverse Reactions during the Operation of Cesarean Delivery. Journal of Kunming Medical University,
[17]	Li Fan. . Journal of Kunming Medical University,
[18]	Xing Wen Zhong . . Journal of Kunming Medical University,
[19]	Xu Ying Fang . . Journal of Kunming Medical University,
[20]	. The Clinical Analysis of 60 Cases of Adverse Reactions caused by Blood Transfusion. Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	王芳，马欢欢，俞建红，周俐慧. 经皮穴位电刺激联合常规药物治疗慢性阻塞性肺疾病急性加重痰浊壅肺证的疗效观察及对肺功能、血清炎性因子的影响. 中国中医药科技. 2025(01): 86-89 .
2.	张萱，观云，段明明，张娜娜，施保柱. 芩桑清热化痰汤治疗痰热郁肺证慢性阻塞性肺疾病急性加重期患者的临床效果. 临床误诊误治. 2025(01): 91-95 .
3.	马玲，王志贤，罗兵. HALP指数对老年慢性阻塞性肺疾病急性加重期患者出院后30 d内非计划再入院的预测价值. 实用心脑肺血管病杂志. 2024(02): 20-23 .
4.	潘小丹，林月华，黄玉龙，范良，郑靓，林承霞，潘燕蝶，张美萃，符秀曼. 雷火灸治疗慢性阻塞性肺疾病急性加重期的疗效观察及对外周血Th17/Treg免疫平衡的影响. 上海针灸杂志. 2024(04): 374-380 .
5.	陈清清，谢菊艳，黄赣英. 慢性阻塞性肺疾病急性加重期患者出院30天内再入院风险预测模型的构建. 健康研究. 2024(04): 446-451 .
6.	杨雪妮. 急诊目标策略下针对性护理对急诊呼吸衰竭患者预后的影响. 中华养生保健. 2024(17): 113-116 .
7.	张昊，米婷，范亚莉，李效清，李青青，许鹏. AECOPD患者T淋巴细胞亚群及血清CD64、TLR2与出院后再次发作的关系. 国际医药卫生导报. 2024(16): 2696-2700 .
8.	胡灏，方正，邓兵，彭俊男，兰艺，王静. 外周血人类软骨糖蛋白39联合嗜酸性粒细胞对慢性阻塞性肺疾病急性加重再入院风险预评估作用分析. 临床军医杂志. 2023(01): 23-26 .
9.	高冬丽，李君霞，陈爽，杨海鹏. 基于肺功能、炎性因子水平变化评价复方异丙托溴铵在慢性阻塞性肺疾病急性加重期患者治疗中的效果. 中国临床医生杂志. 2023(03): 294-296 .
10.	於建平，李国平，陈凯，沈佳程. 慢性阻塞性肺疾病患者外周血单个核细胞CD36 mRNA、血清ApoE水平对急性加重期发生的预测价值. 浙江中西医结合杂志. 2023(09): 816-819+824 .
11.	刘晓玲，赵华，鲁闻燕，章丹，张雪梦，黄晶. 慢性阻塞性肺疾病患者30天再入院风险预测模型的研究进展. 中华急危重症护理杂志. 2023(12): 1142-1146 .